With 2014 coming to a close, The American Journal of Managed Care is taking a look back at the most popular articles from this year. These most-read articles highlight the healthcare issues most important to providers, insurers, and policy makers.
With 2014 coming to a close, The American Journal of Managed Care is taking a look back at the most popular articles across the franchise’s many journals. These most-read articles highlight the healthcare issues most important to providers, insurers, and policy makers.
These articles represent a wide variety of topics, including clinical guidance, medical cost and utilization, and patient satisfaction.
Here are the most popular articles of 2014, in case you missed them the first time around:
1. The JNC 8 Hypertension Guidelines: An In-Depth Guide
By far the most popular article of the year was this guide, which was published in the January issue of Evidence-Based Diabetes Management. The new Joint National Committee (JNC 8) hypertension guidelines advise higher blood pressure goals, reduced use of several types of antihypertensive medications, and emphasized control of systolic blood pressure and diastolic blood pressure with age- and comorbidity-specific treatment cutoffs.
Read the article here.
2. Medical Homes and Cost and Utilization Among High-Risk Patients
This March AJMC paper evaluated the effects of the patient-centered medical home (PCMH) on medical costs and utilization. The authors compared per member per month cost and utilization for members enrolled in PCMH and non-PCMH practices. They found that total costs decreased significantly more for high-risk patients in the PCMH group. The cost decrease was driven by lower inpatient costs as the PCMH group experienced a greater reduction in inpatient admissions over 3 years.
Read the article here.
3. Recurrence of Breast Cancer Years After the Initial Tumor
Evidence-Based Oncology published this analysis of recurrent breast tumors in September. Authors Marj P. Zimmerman, MS, BSPharm, and Stanton R. Mehr wrote that recurrent breast cancer remains a principal cause of death for patients who are initially diagnosed with early-stage disease. As a result, patients who do not demonstrate tumor recurrence for 5 years are no longer considered “cured,” only “cancer-free.”
Read the article here.
4. A Comprehensive Hospital-Based Intervention to Reduce Readmissions for Chronically Ill Patients: A Randomized Controlled Trial
Authors Ariel Linden, DrPH, and Susan W. Butterworth, PhD, wrote in the October issue of AJMC that despite using comprehensive evidence-based intervention components, stand-alone hospitals may be unable to prevent readmissions. An analysis of 512 patients at 2 community hospitals, half assigned to intervention and the others to usual care, found no statistical difference between treatment groups on 30-day readmission incidence rates.
Read the article here.
5. Novel Predictive Models for Metabolic Syndrome Risk: A “Big Data” Analytic Approach
This June AJMC study aimed to accurately predict the risk of metabolic syndrome and its various factors on both a population and individual level. The authors used demographic, medical claim, pharmacy claim, laboratory test, and biometric screening results for nearly 37,000 individuals within Aetna’s database and demonstrated that improving waist circumference and blood glucose yielded the largest benefits on subsequent risk and medical costs.
Read the article here.
6. STABLE Results: Warfarin Home Monitoring Achieves Excellent INR Control
In March, AJMC published the results of a study that found point-of-care patient self-testing at home achieves high-quality warfarin therapy outside of clinical trials. The overall mean of time in therapeutic INR range was 69.7% with close to 30,000 patients studied.
Read the article here.
7. Wait Times, Patient Satisfaction Scores, and the Perception of Care
The authors analyzed the impact of waiting time on patient satisfaction scores by collecting data from more than 11,000 survey responses from patients. The May AJMC paper found that not only are the likelihood to recommend and the overall satisfaction impacted negatively by longer wait times, but perceptions of information, instructions, and the overall treatment provided is also affected by increased wait times.
Read the article here.
8. Is All “Skin in the Game” Fair Game? The Problem With “Non-Preferred” Generics
This Editorial in the September issue of AJMC written by Co-Editor-in-Chief A. Mark Fendrick, MD, and Gerry Oster, PhD, discussed how the increasing demand that patient shoulder larger portions of drug costs is not limited to expensive new medicines like Sovaldi. They highlighted the fact that plans designating “preferred” and “non-preferred” generics are charging patients high co-pays for highly effective and widely used generic drugs sometimes without offering a cheaper “preferred” option.
Read the article here.
9. Mobile Health Clinics in the Era of Reform
In March, an AJMC study characterized the scope of the mobile clinic sector and its impact on access, costs, and quality, as well as the role of mobile clinics during a time of healthcare delivery reform and expanded insurance coverage. These clinics play a critical role in providing high-quality, low-cost care to vulnerable populations, and the authors call for strengthening the ability of these clinics by partnering them with hospitals, health systems, and payers.
Read the article here.
10. Association of Electronic Health Records With Cost Savings in a National Sample
Hospitals that use advanced electronic health records (EHRs) have lower cost per patient admission than comparable hospitals, according to a study published in the June issue of AJMC. The authors analyzed more than 5 million individuals treated at 550 hospitals, 18.9% of which used advanced EHRs. After controlling for patient and hospital characteristics, they found that patients treated at these 104 hospitals with advanced EHRs cost $731 (9.66%) less than patients in hospitals without advanced EHRs.
Read the article here.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions
November 14th 2024The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Read More
Bridging Cancer Care Gaps and Overcoming Medical Mistrust
November 13th 2024In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.
Read More